Research Fees was AbCellera Biologics’s largest product and service line in fiscal 2024, bringing in $26.28M of $28.83M (91%).
| Product and Service | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|---|---|
| Royalty Revenue | $327.35M | $443.03M | — | — | ||
| Research Fees | $19.08M | $40.80M | $35.56M | $26.28M | ||
| Licensing & Royalty Revenue | — | — | $969.00K | $1.05M | ||
| Licensing Revenue | $20.78M | $696.00K | — | — | ||
| Milestone Payments | $8.00M | $900.00K | $1.50M | $1.50M | ||
| Total | $375.20M | $485.42M | $38.03M | $28.83M |
AbCellera Biologics brought in $28.83M from its three product and service lines in fiscal 2024, the year ended December 31, 2024. That was down 24.2% from $38.03M in fiscal 2023. Research Fees was the largest at $26.28M (91.2%), ahead of Milestone Payments at $1.50M (5.2%) and Licensing & Royalty Revenue at $1.05M (3.6%).
Compared with fiscal 2023, Licensing & Royalty Revenue grew fastest, up 8.3% to $1.05M, while Research Fees fell the most, down 26.1% to $26.28M.
AbCellera Biologics began breaking out Licensing & Royalty Revenue in fiscal 2023, when it brought in $969.00K. AbCellera Biologics stopped reporting Royalty Revenue ($443.03M in fiscal 2022) and Licensing Revenue ($696.00K in fiscal 2022) as separate lines.
Canada was AbCellera Biologics’s largest region in fiscal 2024, bringing in $26.20M of $28.90M (91%).
| Geography | FY 2021 | FY 2022 | FY 2023 | FY 2024 |
|---|---|---|---|---|
| Canada | $353.40M | $484.20M | $36.00M | $26.20M |
| United States | $21.80M | — | $2.00M | $2.70M |
| U.S | — | $1.20M | — | — |
| Total | $375.20M | $485.40M | $38.00M | $28.90M |
AbCellera Biologics brought in $28.90M from its two regions in fiscal 2024, the year ended December 31, 2024. That was down 23.9% from $38.00M in fiscal 2023. Canada was the largest at $26.20M (90.7%), ahead of United States at $2.70M (9.3%).
Compared with fiscal 2023, United States grew 35.0% to $2.70M, while Canada fell 27.2% to $26.20M. From fiscal 2021 to 2024, combined revenue from these regions fell from $375.20M to $28.90M, a compound annual decline of 57.5%. Canada's share of the total fell from 94.2% to 90.7%.
AbCellera Biologics stopped reporting U.S as a separate region after fiscal 2022, when it brought in $1.20M.
AbCellera Biologics (ABCL) reports its revenue by product and service and by geography. In fiscal 2024, Research Fees was its largest product and service line, bringing in $26.28M (91.2% of the total), followed by Milestone Payments at $1.50M (5.2%).
Research Fees was AbCellera Biologics' largest product and service line in fiscal 2024, bringing in $26.28M, or 91.2% of the $28.83M total across its three product and service lines.
Canada was AbCellera Biologics' largest region in fiscal 2024, bringing in $26.20M, or 90.7% of the $28.90M total across its two regions.
Among AbCellera Biologics' product and service lines that make up at least 2% of revenue, Licensing & Royalty Revenue grew fastest in fiscal 2024, up 8.3% from $969.00K to $1.05M.
Every figure comes from AbCellera Biologics' annual financial filings, as reported. Each line keeps the name AbCellera Biologics gives it, and years follow its fiscal calendar.
AbCellera Biologics' revenue by product and service goes back to fiscal 2019, with figures through fiscal 2024. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.